| scholarly article | Q13442814 |
| P2093 | author name string | Timothy K Tippin | |
| Thomas M Brundage | |||
| Hervé Momméja-Marin | |||
| Marion E Morrison | |||
| P2860 | cites work | Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations | Q27020967 |
| K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
| The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. | Q30759685 | ||
| Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir | Q33545117 | ||
| Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. | Q33892331 | ||
| The organic anion transporter family: from physiology to ontogeny and the clinic | Q34310328 | ||
| Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate | Q34557258 | ||
| Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans | Q34611138 | ||
| Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans | Q34615572 | ||
| Development of CMX001 for the Treatment of Poxvirus Infections | Q34801704 | ||
| Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria | Q35113383 | ||
| Molecular and cellular physiology of renal organic cation and anion transport | Q35842999 | ||
| First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses | Q35941261 | ||
| Organic anion transporter (Slc22a) family members as mediators of toxicity | Q36104160 | ||
| Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model | Q36734750 | ||
| Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir | Q37488882 | ||
| Measurement and estimation of GFR in children and adolescents | Q37612658 | ||
| Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. | Q39918902 | ||
| Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). | Q40156820 | ||
| The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease | Q41446122 | ||
| CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation | Q42246598 | ||
| Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs | Q43741891 | ||
| Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model | Q44769720 | ||
| Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. | Q44970891 | ||
| Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. | Q46448267 | ||
| Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug | Q71561685 | ||
| Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits | Q71565797 | ||
| P577 | publication date | 2016-11-16 | |
| P1433 | published in | Therapeutic Drug Monitoring | Q15724567 |
| P1476 | title | Brincidofovir Is Not A Substrate For The Human Organic Anion Transporter 1 (Oat1): A Mechanistic Explanation For The Lack Of Nephrotoxicity Observed In Clinical Studies. |
| Q90062923 | Advances in the Development of Therapeutics for Cytomegalovirus Infections |
| Q58609293 | Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via Both Non-Obligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus |
Search more.